Advertisement

Loading...

Nanjing Leads Biolabs Co Ltd

9887.HKHKSE
Healthcare
Biotechnology
HK$88.55
HK$14.55(19.66%)
Hong Kong Market is Open • 10:08

Nanjing Leads Biolabs Co Ltd (9887.HK) Stock Competitors & Peer Comparison

See (9887.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
9887.HKHK$88.00+19.65%14.7B-54.01-HK$1.37N/A
6160.HKHK$185.00+8.12%257.8B115.17HK$1.49N/A
1801.HKHK$90.90+5.57%146.1B160.19HK$0.53N/A
2269.HKHK$34.86+11.16%136.5B25.21HK$1.31N/A
9926.HKHK$139.20+4.58%119.8B-119.45-HK$1.09N/A
1177.HKHK$6.36+8.72%105.3B39.27HK$0.15+1.53%
1530.HKHK$25.32+4.28%53.4B20.77HK$1.09+1.10%
9995.HKHK$110.80+12.09%52.7B65.62HK$1.46N/A
3759.HKHK$20.88+14.29%51.4B19.40HK$0.97+1.16%
2696.HKHK$75.90+8.97%37.9B40.79HK$1.71N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

9887.HK vs 6160.HK Comparison April 2026

9887.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 9887.HK stands at 14.7B. In comparison, 6160.HK has a market cap of 257.8B. Regarding current trading prices, 9887.HK is priced at HK$88.00, while 6160.HK trades at HK$185.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

9887.HK currently has a P/E ratio of -54.01, whereas 6160.HK's P/E ratio is 115.17. In terms of profitability, 9887.HK's ROE is N/A, compared to 6160.HK's ROE of +0.07%. Regarding short-term risk, 9887.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 9887.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions